Alignment Healthcare’s chief experience officer sells $1.35 million in stock

In recent transactions reported to the Securities and Exchange Commission, Hakan Kardes, the Chief Experience Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), sold shares of the company’s common stock. The transaction comes as ALHC trades near its 52-week high of $16.25, having delivered an impressive 183% return over the past year. On March 6, Kardes sold 86,659 shares at a weighted-average price of $15.53, totaling approximately $1.35 million. This sale was conducted to cover tax withholding obligations related to the vesting of performance share units (PSUs).

Earlier, on March 4, Kardes acquired 474,208 shares at no cost. These shares were granted upon the certification of the achievement of performance objectives under PSUs, with half of the units vested immediately and the remainder scheduled to vest on December 31, 2025, contingent upon continued service with the company. According to InvestingPro data, analysts maintain a bullish outlook on ALHC, with price targets ranging from $9 to $21.

Following these transactions, Kardes holds 682,993 shares of Alignment Healthcare’s common stock. For deeper insights into ALHC’s valuation and growth prospects, InvestingPro subscribers can access exclusive financial health scores and 8 additional ProTips that provide crucial context for investors tracking insider movements.

In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16, compared to the forecast of -0.18, and revenue reaching $701.2 million against the expected $674.97 million. The company achieved its first year of adjusted EBITDA profitability and saw a significant 59% membership growth in 2024. Looking forward, Alignment Healthcare has issued revenue guidance for 2025, projecting between $3.72 billion and $3.78 billion, with adjusted gross profit expected to range from $415 million to $445 million. Analysts at Raymond (NSE:RYMD) James responded by increasing the price target for Alignment Healthcare to $19.00, citing the company’s robust performance and potential for continued growth. Piper Sandler also raised its price target to $21.00, maintaining an Overweight rating and highlighting the company’s scalable "flywheel" approach. This strategy is noted for improving patient engagement and achieving high Star Ratings, which are essential for member retention and cost management. Both firms express confidence in Alignment Healthcare’s ability to expand its business model across various states.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.